HAX1 and breast carcinoma: Overall survival (OS) and distant recurrence-free survival (DRFS) for 46 breast cancer patients were also evaluated by 3 different univariate and multivariate analyzes, in which the HAX1 protein expression, either cytoplasmic, nuclear, or cumulative, was assessed by IHC (Table 1).